PURPOSE: VEGF production by RPE cells has been shown to be important in regulating aberrant angiogenesis in the retina, which is responsible for multiple types of ocular pathology. EMP2 is highly expressed in the RPE and has been shown to regulate FAK activation, which is implicated in VEGF expression in other cell lines. The purpose of this study was to determine whether EMP2 regulates VEGF expression in the RPE cell line, ARPE-19. METHODS: ARPE-19 cells were engineered to overexpress EMP2. EMP2 siRNA was used to decrease EMP2 expression. The small molecule inhibitor PP2 was used to inhibit FAK activation. VEGF levels were measured by Western blot and ELISA. Functional differences in secreted VEGF were assayed using HUVEC migration. RESULTS: VEGF expression levels correlated with levels of EMP2. An increase of VEGF by 150% was observed in EMP2 overexpressing cells as compared with ARPE-19 cells. Concordantly, EMP2 knockdown resulted in a 57% decrease in VEGF expression. HUVEC migration (P = 0.01) and vessel tube formation (P < 0.01) were significantly increased when exposed to cell culture supernatants from EMP2 overexpressing cells. CONCLUSIONS: This study establishes a novel connection between EMP2 and VEGF and may reflect either a direct effect through the tetraspan web or an indirect change through FAK activation. This connection is functionally significant. In addition to the direct use of anti-VEGF antibodies, modulation of EMP2 with impact on VEGF is potentially a distinct therapeutic target for the treatment of neovascularization associated with retinal diseases that involve pathologic angiogenesis.
PURPOSE:VEGF production by RPE cells has been shown to be important in regulating aberrant angiogenesis in the retina, which is responsible for multiple types of ocular pathology. EMP2 is highly expressed in the RPE and has been shown to regulate FAK activation, which is implicated in VEGF expression in other cell lines. The purpose of this study was to determine whether EMP2 regulates VEGF expression in the RPE cell line, ARPE-19. METHODS: ARPE-19 cells were engineered to overexpress EMP2. EMP2 siRNA was used to decrease EMP2 expression. The small molecule inhibitor PP2 was used to inhibit FAK activation. VEGF levels were measured by Western blot and ELISA. Functional differences in secreted VEGF were assayed using HUVEC migration. RESULTS:VEGF expression levels correlated with levels of EMP2. An increase of VEGF by 150% was observed in EMP2 overexpressing cells as compared with ARPE-19 cells. Concordantly, EMP2 knockdown resulted in a 57% decrease in VEGF expression. HUVEC migration (P = 0.01) and vessel tube formation (P < 0.01) were significantly increased when exposed to cell culture supernatants from EMP2 overexpressing cells. CONCLUSIONS: This study establishes a novel connection between EMP2 and VEGF and may reflect either a direct effect through the tetraspan web or an indirect change through FAK activation. This connection is functionally significant. In addition to the direct use of anti-VEGF antibodies, modulation of EMP2 with impact on VEGF is potentially a distinct therapeutic target for the treatment of neovascularization associated with retinal diseases that involve pathologic angiogenesis.
Authors: S K Mitra; D Mikolon; J E Molina; D A Hsia; D A Hanson; A Chi; S-T Lim; J A Bernard-Trifilo; D Ilic; D G Stupack; D A Cheresh; D D Schlaepfer Journal: Oncogene Date: 2006-05-08 Impact factor: 9.867
Authors: Madhuri Wadehra; Ashley Forbes; Natasha Pushkarna; Lee Goodglick; Lynn K Gordon; Carmen J Williams; Jonathan Braun Journal: Dev Biol Date: 2005-10-10 Impact factor: 3.582
Authors: Shawn A Morales; Sergey Mareninov; Pradeep Prasad; Madhuri Wadehra; Jonathan Braun; Lynn K Gordon Journal: Exp Eye Res Date: 2007-08-29 Impact factor: 3.467
Authors: Shawn A Morales; Sergey Mareninov; Madhuri Wadehra; Lily Zhang; Lee Goodglick; Jonathan Braun; Lynn K Gordon Journal: Invest Ophthalmol Vis Sci Date: 2008-05-09 Impact factor: 4.799
Authors: Kaori Shimazaki; Eric J Lepin; Bo Wei; Agnes K Nagy; Catherine P Coulam; Sergey Mareninov; Maoyong Fu; Anna M Wu; James D Marks; Jonathan Braun; Lynn K Gordon; Madhuri Wadehra Journal: Clin Cancer Res Date: 2008-11-15 Impact factor: 12.531
Authors: Magali Saint-Geniez; Arindel S R Maharaj; Tony E Walshe; Budd A Tucker; Eiichi Sekiyama; Tomoki Kurihara; Diane C Darland; Michael J Young; Patricia A D'Amore Journal: PLoS One Date: 2008-11-03 Impact factor: 3.240
Authors: Heon Yung Gee; Shazia Ashraf; Xiaoyang Wan; Virginia Vega-Warner; Julian Esteve-Rudd; Svjetlana Lovric; Humphrey Fang; Toby W Hurd; Carolin E Sadowski; Susan J Allen; Edgar A Otto; Emine Korkmaz; Joseph Washburn; Shawn Levy; David S Williams; Sevcan A Bakkaloglu; Anna Zolotnitskaya; Fatih Ozaltin; Weibin Zhou; Friedhelm Hildebrandt Journal: Am J Hum Genet Date: 2014-05-08 Impact factor: 11.025
Authors: Jennifer R Dungan; Xue Qin; Simon G Gregory; Rhonda Cooper-Dehoff; Julio D Duarte; Huaizhen Qin; Martha Gulati; Jacquelyn Y Taylor; Carl J Pepine; Elizabeth R Hauser; William E Kraus Journal: Am Heart J Plus Date: 2022-06-14
Authors: Michel M Sun; Ann M Chan; Samuel M Law; Sergio Duarte; Daniel Diaz-Aguilar; Madhuri Wadehra; Lynn K Gordon Journal: Invest Ophthalmol Vis Sci Date: 2019-01-02 Impact factor: 4.799